Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Spectrum Pharmaceuticals, Inc.
The investigation concerns whether Spectrum and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
On October 23, 2015, Spectrum announced that it has received a Complete Response Letter from the from the FDA in response to its New Drug Application seeking clearance for CE-Melphalan, indicating that the FDA cannot approve the application in its present form. The company did not specify the nature of the deficiencies, and only stated that there were none of a clinical nature.
Following this news, shares of Spectrum fell $1.64 or 24.70% during pre-market trading on October 23, 2015.
If you are aware of any facts relating to this investigation, or purchased shares of Valeant, you can assist this investigation by contacting Peretz Bronstein or his Investor Relations Coordinator Eitan Kimelman of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email email@example.com. Those who inquire by e-mail are encouraged to include their mailing address, email and telephone number.